Delcath Systems Lifts 2026 Revenue Outlook to $104M–$108M Following a Strong Q2 Beat
DCTH sits 76% above its 52-week low of $8.12.
Summary
Delcath Systems exceeded Q2 estimates with $29.1M in revenue and raised its full-year 2026 guidance to $104M–$108M, fueled by strong HEPZATO adoption and a growing network of treatment centers.
Updates
· SEC 10-Q — The 10-Q shows Q2 product revenue of $29.13M, net income of $2.67M, and HEPZATO KIT revenue of $27.16M. It also discloses $16.0M remaining under the share repurchase program.
Key Events · Earnings and Guidance · DCTH
-
Q2 Revenue Beat and Raised Guidance
Revenue for the second quarter reached $29.1M, beating the $26.26M consensus by 11%. Full-year 2026 guidance was raised to $104M–$108M, implying at least 28% growth in HEPZATO volume over 2025.
-
Strong Profitability and Cash Generation
Gross margin hit 90%, net income came in at $2.7M, and adjusted EBITDA was $7.6M. Operating cash flow totaled $5.7M, with cash and investments of $95.9M and no debt on the balance sheet.
-
Expanding Treatment Network and Volume
The company now has 31 active treatment centers, and HEPZATO procedure volume grew approximately 30% year-over-year, reflecting increasing physician adoption.
-
Clinical Pipeline Progress
The first patient was dosed in a global Phase 2 trial of HEPZATO for metastatic breast cancer; positive retrospective data were presented at ESMO Breast Cancer 2026; and two investigator-initiated trials in melanoma were presented at ASCO 2026.
Analysis · DCTH · Industrial Applications And Services
A robust second quarter saw Delcath deliver revenue of $29.1 million, topping consensus by 11%, and prompted management to raise full-year 2026 guidance to $104–$108 million — implying at least 28% growth in HEPZATO volume. Gross margins reached 90%, and the company generated $5.7 million in operating cash flow, ending the quarter with $95.9 million in cash and no debt. The raised outlook and an expanding treatment center network underscore accelerating commercial traction for its liver-directed therapy platform.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36% of the 1040 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCTH was trading at $14.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $436M. The 52-week trading range was $8.12 to $13.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.